BSA
VRTX icon

Braun Stacey Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Braun Stacey Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-44,672
Closed -$21.7M – 126
2025
Q1 		$21.7M Sell
44,672
-778
-2% -$363K 0.89% 51
2024
Q4 		$18.3M Sell
45,450
-6,047
-12% -$2.8M 0.68% 61
2024
Q3 		$24M Sell
51,497
-5,361
-9% -$2.58M 0.91% 42
2024
Q2 		$26.7M Sell
56,858
-2,664
-4% -$1.16M 1.03% 31
2024
Q1 		$24.9M Sell
59,522
-803
-1% -$339K 0.98% 38
2023
Q4 		$24.5M Sell
60,325
-557
-0.9% -$206K 1.1% 28
2023
Q3 		$21.2M Sell
60,882
-173
-0.3% -$60.5K 1.03% 37
2023
Q2 		$21.5M Sell
61,055
-35,615
-37% -$12M 1% 36
2023
Q1 		$30.5M Buy
+96,670
New +$29M 0.8% 61
2020
Q4 		– Sell
-65,312
Closed -$17.8M – 139
2020
Q3 		$17.8M Sell
65,312
-670
-1% -$185K 0.95% 36
2020
Q2 		$19.2M Buy
65,982
+7,099
+12% +$1.92M 1.1% 19
2020
Q1 		$14M Buy
+58,883
New +$13.5M 1.07% 34

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Braun Stacey Associates's VRTX Position: Q2 2025 in Review

Braun Stacey Associates sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 44,672 shares — an estimated $21.7M sold.

Braun Stacey Associates first reported a position in VRTX in Q1 2020 and held it in 12 quarters. The position peaked at $30.5M in Q1 2023. 1,562 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • Braun Stacey Associates reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Braun Stacey Associates sold 44,672 Vertex Pharmaceuticals shares in Q2 2025, an estimated $21.7M.
  • Braun Stacey Associates first reported a position in Vertex Pharmaceuticals in Q1 2020 and held it in 12 quarters.
  • Braun Stacey Associates's Vertex Pharmaceuticals position peaked at $30.5M in Q1 2023.
  • 1,562 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Braun Stacey Associates's 13F filing for Q2 2025, filed 12 Aug 2025.